Home › Diffuse Large B-Cell Lymphoma › Georgia
Pag-aaral pangklinika para sa Diffuse Large B-Cell Lymphoma sa Georgia
14 pag-aaral para sa Diffuse Large B-Cell Lymphoma ang naghahanap ng mga kalahok sa mga site sa Georgia.
Mga Lungsod sa Georgia
Opisyal na teksto ng pag-aaral (English)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Augusta University, Augusta
- Southeastern Regional Medical Center, Newnan
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05006716A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- University Cancer & Blood Center, LLC ( Site 0141), Athens
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06717347A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Emory University Hospital, Atlanta
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07226843Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Augusta University Georgia Cancer Center, Augusta
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 31, 2026 · NCT06500273Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- City of Hope Atlanta Cancer Center, Newnan
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT07365306Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Augusta University Medical Center, Augusta
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05826535A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Winship Cancer Institute of Emory University, Atlanta
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT04104776A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Northside Hospital, Atlanta
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Winship Cancer Institute of Emory University, Atlanta
- Georgia Cancer Center at Augusta University, Augusta
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT04792489Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT03501576A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Winship Cancer Institute of Emory University, Atlanta
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT05131022SynKIR-310 for Relapsed/Refractory B-NHL
- Winship Cancer Institute of Emory University, Atlanta
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 14, 2026 · NCT06544265Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 2, 2026 · NCT05633615DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Blood and Marrow Transplant Group of Georgia, Atlanta
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 7, 2023 · NCT04920617Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.